DUBLIN--(BUSINESS WIRE)--May 14, 2018--The "Market Spotlight: Hidradenitis Suppurativa" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Hidradenitis Suppurativa market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, epidemiology, and drug-specific revenue forecasts.

Key Takeaways

All approved drugs for hidradenitis suppurativa target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, except for Humira, which is both an intravenous and a subcutaneous formulation. Pipeline therapies for hidradenitis suppurativa include two Phase II drugs and one drug in BLA phase. All the pipeline therapies are administered via the subcutaneous or intravenous routes. Therapies in development for hidradenitis suppurativa target tumor necrosis factor-alpha and interleukin-17. All of the pipeline therapies are administered via the subcutaneous or intravenous routes. The Netherlands has a lead in the number of hidradenitis suppurativa clinical trials globally. Abott has the highest number of completed clinical trials for hidradenitis suppurativa, with two completed trials. AbbVie is the only sponsor which has carried out a Phase III trial in hidradenitis suppurativa.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Hidradenitis Suppurativa Subtypes

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS IN THE US

KEY REGULATORY EVENTS

BI's Cyltezo Becomes 15th EU Biosimilar This Year, Adds To Pressure On Humira

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Samsung Bioepis Builds Its Biosimilars Name In Europe

EU CHMP OKs Imraldi, Samsung Bioepis' Biosimilar Of AbbVie's Humira

Amgen's Biosimilar Adalimumab First To EU Nod But No Launch

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

For more information about this report visit https://www.researchandmarkets.com/research/7qjndh/hidradenitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006246/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Dermatological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 03:01 PM/DISC: 05/14/2018 03:01 PM

http://www.businesswire.com/news/home/20180514006246/en